The laboratory is equipped with state-of-the-art technology to perform polychromatic Flow Cytometry, including 5-functional intracellular cytokine staining, 8-colour immunophenotyping, cytometric bead arrays and different IGRAs (in house ELISPOT, Quantiferon, TB-SPOT), which allow to perform sophisticated cellular immunology research. The humoral immunology section is currently under development. assays be applied in the near future. The Immunology Laboratory is associated with a large PBMC processing laboratory, allowing a high throughput of samples.
The laboratory is currently involved in immunogenicity testing during a phase 2 HIV vaccine Trial, in the evaluation of TB diagnostics, and furthermore focuses on basic research, studying the interplay between different infectious pathogens, such as HIV, Mycobacterium tuberculosis and helminths with the human immune system.
These studies have led to the identification of important immune correlates of protection from HIV disease progression and provide a potential mechanism for the greatly increased susceptibility of HIV-infected subjects to develop active Tuberculosis.
Current areas of research:
- Evaluating the immunogenicity of HIV vaccine candidates during clinical trials.
- Characterization of the HIV- and Mycobacterium tuberculosis (MTB)-specific T cell responses and identification of immune correlates of immune protection
- Immune modulation by Helminth infections in relation to HIV susceptibility, pathogenesis and disease progression.
- Helminth infection and Allergies
- Evaluation of new diagnostic tools for Tuberculosis
Current Team members:
Dr. Asli Bauer, PhD, Supervisor
Mkunde Chachage, PhD student , Junior scientist
Antelmo Haule, BSc, Section Supervisor
Maria Mwakatima, Laboratory Scientist
Lwitiho E. Sudi, Laboratory Scientist
Prisca P. Mviombo, Lab technician
Onesmo P. Mgaya, Lab technician
Dr. Christof Geldmacher, PhD, LMU, Scientific advisor
Selected scientific publications
- Preferential infection and depletion of Mycobacterium tuberculosis (MTB)-specific CD4 T cells after HIV-1 infection. Geldmacher & Ngwenyama et al. J. Exp. Med 2010 (in press)
- CD8 T-cell recognition of multiple epitopes within specific Gag regions is associated with maintenance of a low steady-state viremia in human immunodeficiency virus type 1-seropositive patients. Geldmacher et al. J Virol. 2007 Mar; 81(5):2440-8.
- Minor viral and host genetic polymorphisms can dramatically impact the biological outcome of an epitope-specific CD8 T cell response. Geldmacher et al. Blood 2009 Aug 20;114(8):1553-62.
- Early Depletion of Mycobacterium tuberculosis–Specific T Helper 1 Cell Responses after HIV-1 Infection. Geldmacher et al. J Infect Dis. 2008 Dec 1;198(11):1590-8
- In a mixed subtype epidemic, the HIV-1 Gag-specific T-cell response is biased towards the infecting subtype. Geldmacher et al. AIDS 2007 Jan 11; 21(2):135-43.
- A high viral burden predicts the loss of CD8 T-cell responses specific for subdominant gag epitopes during chronic human immunodeficiency virus infection. Geldmacher et al. J Virol. 2007 Dec; 81(24):13809-15.